•
Considering a Data-Driven, Risk-Based Approach to Easing COVID-19 Lockdowns Across America
Talks about Social Distancing, Covid-19 and Risk Analysis
PK
Peter Kolchinsky
Steering Committee Member at No Patient Left Behind
Boston, Massachusetts
Overview
Peter Kolchinsky is a Managing Partner at RA Capital Management, LP, where he has successfully invested in various biotech companies at different funding stages, including Gameto, SeLux Diagnostics, and Freenome. He is also a Steering Committee Member of No Patient Left Behind and a Board Member of the National Academy of Sciences, Board on Global Science and Technology.
Kolchinsky's career highlights include his leadership in managing a successful biotech fund and advocating for reform in the healthcare sector through his involvement in organizations like No Patient Left Behind and the National Academy of Sciences.
Work Experience
Managing Partner
2001 - Current
RA Capital is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. Anyone wishing to discuss their business should not reach out through LinkedIn (I check my account rarely); please visit our firm's website for contact details and you will most certainly be routed to the right people.
Steering Committee Member
2020
No Patient Left Behind is a network of biotechnology innovators, investors, and healthcare professionals advocating for access to medicines.
Board Member, Board on Global Science and Technology
2009 - 2012